The FOXTROT trial demonstrated that osocimab, a factor XIa-inhibitor, was non-inferior to enoxaparin in the prevention of VTE up to 10-13 days after knee arthroplasty.
Sacubitril-valsartan was well tolerated in stable HFrEF patients in a real-world population. Target dose was achieved in most patients and was linked to down-titration of diuretic dose.
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.
This prospective study showed that 6 months training and completion of a first-time marathon results in a reduction in blood pressure and aortic stiffness in healthy participants.
DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.
Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.
A longitudinal study in Japan revealed that being overweight/obese at age 3, or having had an overweight/obese mother before she was pregnant is predictive of overweight/obesity at 15 years in girls.
How can high levels of triglyceride-rich lipoproteins lead to myocardial infarction? Prof. Nordestgaard gives a presentation on mechanisms by which triglycerides can lead to CV events.
Three phenogroups were identified in TOPCAT HFpEF patients, ranging from a low-risk group with mild symptoms to a high-risk obese, diabetic group with advanced symptoms that responded well to spironolactone.
Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.
This pilot RCT in acute decompensated HF patients showed that empagliflozin did not result in reduction of primary endpoints, but did reduce a combined endpoint of worsening HF, rehospitalization for HF or death compared to placebo.
The Phase III STRENGTH trial evaluating the effect of a fish oil-derived mixture of free fatty acids on CV outcomes in patients with mixed dyslipidemia and high CVD risk is closed due to a low likelihood to show benefit.